XML 78 R63.htm IDEA: XBRL DOCUMENT v3.22.0.1
Earnings Per Share (Details)
$ / shares in Units, shares in Thousands, $ in Thousands
6 Months Ended 12 Months Ended
Dec. 31, 2020
USD ($)
Jun. 17, 2020
USD ($)
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
Earnings Per Share [Abstract]          
Exchange ratio     1    
Numerator          
Net income (loss) $ 1,077,069 $ 624,885 $ 1,241,201 $ 1,701,954 $ 2,461,419
Less: net income attributable to Continuing Investors Partnerships prior to the IPO       479,842  
Less: net income attributable to non-controlling interest     621,473 726,914 $ 112,884
Net income attributable to Royalty Pharma plc - basic and diluted     619,728 495,198  
Net income attributable to Royalty Pharma plc - basic and diluted     $ 619,728 $ 495,198  
Denominator          
Weighted average Class A ordinary shares outstanding - basic (in shares) | shares [1]     414,794 375,444  
Unvested RSUs (in shares) | shares     8 11  
Weighted average Class A ordinary shares outstanding - diluted (in shares) | shares [1]     414,802 375,455  
Earnings per Class A ordinary share - basic (in dollars per share) | $ / shares [1]     $ 1.49 $ 1.32  
Earnings per Class A ordinary share - diluted (in dollars per share) | $ / shares [1]     $ 1.49 $ 1.32  
Common Class A          
Denominator          
Weighted average Class A ordinary shares outstanding - diluted (in shares) | shares     607,176 607,111  
Class B Holders          
Numerator          
Less: net income attributable to non-controlling interest     $ 297,321 $ 316,993  
Legacy Investors Partnerships and RPSFT          
Numerator          
Less: net income attributable to non-controlling interest     $ 324,152 $ 409,921  
[1] Represents earnings per Class A ordinary share and weighted average Class A ordinary shares outstanding for the period from June 16, 2020 through December 31, 2020 following our initial public offering (“IPO”) in the year ended December 31, 2020. See Note 13–Earnings per Share.